nucala powder for solution for injection
glaxo smith kline (israel) ltd - mepolizumab - powder for solution for injection - mepolizumab 100 mg - mepolizumab - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patientschronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with corticosteroids and surgery in the last 10 years do not provide adequate disease control.eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (egpa).hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.
nucala 100mg powder for solution for injection vials
glaxosmithkline uk ltd - mepolizumab - powder for solution for injection - 100mg
nucala 100mg powder for solution for injection
glaxosmithkline pharmaceutical sdn. bhd. - mepolizumab -
nucala 100 mg powder for solution for injection
glaxo saudi arabia ltd, saudi arabia - mepolizumab - powder for solution for injection - 100 mg
nucala 100 mg powder for solution for injection
glaxo saudi arabia ltd, saudi arabia - mepolizumab - powder for solution for injection - 100 mg
nucala mepolizumab 100 mg solution for injection in pre-filled pen
glaxosmithkline australia pty ltd - mepolizumab, quantity: 100 mg - injection, solution - excipient ingredients: sucrose; dibasic sodium phosphate heptahydrate; citric acid monohydrate; polysorbate 80; disodium edetate; water for injections - severe eosinophilic asthma,nucala is indicated as an add-on treatment for severe eosinophilic asthma in patients aged 12 years and over (see section 5.1 pharmacodynamic properties, clinical trials).,chronic rhinosinusitis with nasal polyps (crswnp),nucala is indicated as add-on treatment in adult patients (18 years and above) with severe chronic rhinosinusitis with nasal polyps (crswnp) with an inadequate response to intranasal corticosteroids (see section 5.1 pharmacodynamic properties, clinical 2 trials).,relapsed or refractory egpa,nucala is indicated as an add-on treatment for relapsing or refractory eosinophilic granulomatosis with polyangiitis (egpa) in adult patients aged 18 years and over (see section 5.1 pharmacodynamic properties, clinical trials).
nucala mepolizumab 100 mg solution for injection in pre-filled syringe
glaxosmithkline australia pty ltd - mepolizumab, quantity: 100 mg - injection, solution - excipient ingredients: sucrose; dibasic sodium phosphate heptahydrate; citric acid monohydrate; polysorbate 80; disodium edetate; water for injections - severe eosinophilic asthma,nucala is indicated as an add-on treatment for severe eosinophilic asthma in patients aged 12 years and over (see section 5.1 pharmacodynamic properties, clinical trials).,chronic rhinosinusitis with nasal polyps (crswnp),nucala is indicated as add-on treatment in adult patients (18 years and above) with severe chronic rhinosinusitis with nasal polyps (crswnp) with an inadequate response to intranasal corticosteroids (see section 5.1 pharmacodynamic properties, clinical 2 trials).,relapsed or refractory egpa,nucala is indicated as an add-on treatment for relapsing or refractory eosinophilic granulomatosis with polyangiitis (egpa) in adult patients aged 18 years and over (see section 5.1 pharmacodynamic properties, clinical trials).
nucala powder for solution for injection 100mg
glaxosmithkline pte ltd - mepolizumab - injection, powder, lyophilized, for solution - mepolizumab 100mg/vial
nucala powder for solution
glaxosmithkline inc - mepolizumab - powder for solution - 100mg - mepolizumab 100mg - immunosuppressive agents
nucala 100mg/ml solution for injection in pre-filled syringe (safety syringe)
glaxosmithkline pharmaceutical sdn. bhd. - mepolizumab -